Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Daito Pharmaceutical Co., Ltd. Revises Dividend to ¥17.9
Source disclosure: January 16, 2026
Daito Pharmaceutical Co., Ltd. [4577.T]
TOKYO (Pulse News Wire) — Daito Pharmaceutical Co., Ltd. [4577.T] corrected its dividend forecast for the fiscal year ending May 2026.
The dividend was revised to ¥17.9 from ¥251.4 per share. The correction was disclosed on January 16, 2026 after errors were identified in the interim earnings report.
AI-translated content. 🟢 Confidence: High See terms • Original filing
💬 Help us improve transla
TOKYO (Pulse News Wire) — Daito Pharmaceutical Co., Ltd. [4577.T] corrected its dividend forecast for the fiscal year ending May 2026.
The dividend was revised to ¥17.9 from ¥251.4 per share. The correction was disclosed on January 16, 2026 after errors were identified in the interim earnings report.
